

Pharmacy Drug Policy Checklist

POLICY NAME Evrysdi (risdiplam) POLICY # 2791P

Criteria

Coverage Criteria		
	Diagnosis of Spinal Muscular Atrophy (SMA) types I, II, or III	
	Documentation of 5q SMA double gene mutation, double gene deletion, or compound heterozygote	
	Prescribed by a Geneticist (gene specialist) or provider specializing in the treatment of SMA	
	Documented baseline motor milestone scores according to one of the following age-appropriate assessments: • Hammersmith Infant Neurologic Exam (HINE) • Modified Hammersmith Functional Motor-Scale • Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) • Bayley Scales of Infant and Toddler Development • Motor Function Measure 32 (MFM32)	
	Chart notes from a recent specialist visit detailing member's present disease progression and respiratory function (patient does not require invasive ventilatory support)	
	Review of chart notes documenting diagnosis and confirming that patient has met all of the requirements for treatment with Evrysdi by both a pharmacist and medical director	

Exclusion Criteria – Any of the following prevents coverage

Evrysdi will not be covered after treatment with Zolgensma because its use following Zolgensma
infusion is currently in clinical trials without confirmed efficacy data and is currently considered
experimental/investigational

- Note: Patients in the clinical trials that received Zolgensma before the age of 2 years were followed up to 5 years post-treatment and did not require additional medications
- Requests for Evrysdi in members that have previously been treated with Zolgensma will be reviewed by a Medical Director for medical necessity
- Evrysdi will not be covered in combination with Spinraza because the concomitant use of these two drugs has not been studied and is considered experimental/investigational
 - Requests for Evrysdi in members that have previously been treated with Spinraza will be reviewed by a Medical Director for medical necessity

Replacement of lost, wasted, or discarded doses will not be covered. References • Health Alliance's standard refill threshold will apply